Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Acapatamab · AMG-160

Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (CD3E) · developed by AMGEN

Phase 1 Most advanced trial (none active)
AMGN Developer
1 Registered trials

What is Acapatamab?

Acapatamab is a half-life extended bispecific T-cell engager composed of two single-chain variable fragments, one binding PSMA on prostate cancer cells and one binding CD3 on cytotoxic T lymphocytes. It redirects T cells to PSMA-expressing tumor cells, causing their destruction. It is being studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-160
Drug type
Bispecific antibody
Targets
prostate-specific membrane antigen (PSMA) (FOLH1), CD3 (CD3E)
Mechanism
Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (CD3E)
Pathways
T-cell redirection and CTL-mediated killing of tumor cells
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
GW5EID3IDO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03792841 Phase 1 Metastatic Castration-resistant Prostate Cancer Terminated AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate CancerProstate Cancer

Other drugs acting on FOLH1 / CD3E

More from AMGEN

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Acapatamab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.